Releasing the brake on the immune system: ipilimumab in melanoma and other tumors - Wikidata - wikimedia - TriplyDB

Releasing the brake on the immune system: ipilimumab in melanoma and other tumors

Releasing the brake on the immune system: ipilimumab in melanoma and other tumors

http://www.wikidata.org/entity/Q34447732

about

Thunder and lightning: immunotherapy and oncolytic viruses collide Concordance of preclinical and clinical pharmacology and toxicology of therapeutic monoclonal antibodies and fusion proteins: cell surface targets Evolving landscape and novel treatments in metastatic castrate-resistant prostate cancer Novel non-AR therapeutic targets in castrate resistant prostate cancer Adverse Events Associated with Immune Checkpoint Blockade in Patients with Cancer: A Systematic Review of Case Reports Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort.Risk of hepatotoxicity in cancer patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis of published data.Ipilimumab treatment decreases monocytic MDSCs and increases CD8 effector memory T cells in long-term survivors with advanced melanoma.Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases Therapy preferences in melanoma treatment--willingness to pay and preference of quality versus length of life of patients, physicians and healthy controls.The immune response to tumors as a tool toward immunotherapy.Association of CTLA-4 polymorphisms with improved overall survival in melanoma patients treated with CTLA-4 blockade: a pilot study.Sipuleucel-T for therapy of asymptomatic or minimally symptomatic, castrate-refractory prostate cancer: an update and perspective among other treatments.Immunotherapy treatments for small-cell lung cancer: past, present and future.Using lymph node swelling as a potential biomarker for successful vaccination.Treatment of brain metastases: chemotherapy.Tumor control versus adverse events with targeted anticancer therapies.Multifocal radiculoneuropathy during ipilimumab treatment of melanoma.Novel targets in the treatment of advanced melanoma: new first-line treatment options.Immune-mediated adverse events associated with ipilimumab ctla-4 blockade therapy: the underlying mechanisms and clinical management.Cellular and molecular mechanisms in cancer immune escape: a comprehensive review.Diet, obesity, and cancer progression: are adipocytes the link?Genetic and molecular targets in lymphoma: implications for prognosis and treatment.Ipilimumab-induced necrotic myelopathy in a patient with metastatic melanoma: A case report and review of literature.Immunotherapeutic approaches for cancer therapy: An updated review.Systematic review: colitis associated with anti-CTLA-4 therapy.Synergy of molecular targeted approaches and immunotherapy in melanoma: preclinical basis and clinical perspectives.Stimulating immune responses to fight cancer: Basic biology and mechanisms.Biomarkers associated with checkpoint inhibitors.Monitoring and Management of Immune-Related Adverse Events Associated With Programmed Cell Death Protein-1 Axis Inhibitors in Lung Cancer.VISTA is a novel broad-spectrum negative checkpoint regulator for cancer immunotherapy.Expression and clinical significance of MAGE and NY-ESO-1 cancer-testis antigens in adenoid cystic carcinoma of the head and neck Ipilimumab: Melanoma and beyond.How Checkpoint Inhibitors Are Changing the Treatment Paradigm in Solid Tumors: What Advanced Practitioners in Oncology Need to Know.Using MRI cell tracking to monitor immune cell recruitment in response to a peptide-based cancer vaccine.Ipilimumab-Induced Gastrointestinal Toxicities: A Management Algorithm.Capitalizing on Cancer Specific Replication: Oncolytic Viruses as a Versatile Platform for the Enhancement of Cancer Immunotherapy Strategies.Evaluation of CTLA-4 expression and relevance as a novel prognostic factor in patients with non-small cell lung cancer.Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial Bilateral anterior uveitis after immunotherapy for malignant melanoma

P2860

Q24597894-CE06C258-AAA1-449E-9E67-C4DBFC175C7A Q26830569-C68D4CD0-68C7-4EAA-B357-A2DE8726AB9D Q27010542-EC25A064-DBEE-476E-B8D2-9EFB15B1F87B Q28383663-B9F4A1D4-544C-4694-BD68-06BD1D4BF879 Q28553328-D8C91EA4-8401-4815-9968-6AFF0B4D9BA1 Q30828178-4A0507F2-F676-4341-A434-55CD5D3A792B Q31171172-B28EB149-D87D-4609-8E78-C3BF7D87C94E Q33591598-B8AE5BDA-ABFB-4AF3-B39E-FD365AB5475B Q33620317-247034E0-9A62-4048-94A0-1C33A2E54BB6 Q34450266-2CB8468B-9A31-4543-96D5-3F98DD122358 Q34634545-79583D89-1E7C-4A7E-A796-0A3C17135459 Q34651347-D6A28FE4-F00B-4E5B-9A2A-89DC667BB144 Q35128716-63DF9253-5711-49F9-866F-06A828048AD9 Q35904003-85C6299D-21FD-4FC2-A169-515C45A8B857 Q36032562-D4ECC3F2-D96A-4186-A7CB-61BB769E6E5B Q37967507-544B30C8-7C5B-4EF1-A13A-7B23CA39D595 Q37969899-880844FB-AE47-4431-B5D3-2507337B7F0D Q38085259-90F86DD6-5FC0-48E3-9466-F767341BF55A Q38095228-6353CF1B-F271-40BA-AD1B-AA4C63EDD0C8 Q38166382-46CFBB63-590C-4F84-9DA2-BCAD16F50623 Q38170150-09A72F79-1D5E-478F-BEF7-92206AE3AA8C Q38256347-7A3ABB6B-C36F-4309-9382-77BFA5E0A4DD Q38294626-C55ECC6C-9A10-483E-8CAF-53BF18E7CCDE Q38364937-C01045B8-5512-4280-BAEA-E3A126F68B6F Q38388102-BE313BA9-7A24-4A11-95D3-D324B0DB38B0 Q38529051-D26D045C-CC95-4B8D-9138-76A4CB308AF0 Q38553161-109A9D3D-DD72-42BE-BA96-16729D338B7C Q38578898-B304ECAE-33E1-4FE5-9445-48C2E70896DC Q38819537-7A5F3A29-4492-4EAC-A648-38D6FD1557E9 Q38930084-3E1C347C-94CD-4867-9895-5F080FD2B835 Q39181190-89E76D47-51E2-4E51-9050-A2558DF013D9 Q39999283-598870A8-D80D-42CE-A06B-C5343ACC4B3A Q40104280-048F2913-C065-4032-A975-976CEAB9B950 Q47120953-D18D9BA9-8B7D-4549-AD26-54EF0E08FCD9 Q47296148-8E1B356E-EC94-47B8-BABF-872665D3189D Q50719439-2A77EA52-D1D5-4FA9-B7C3-38CDE994C6D4 Q50865520-609A9BF6-390B-4455-A9C3-523C85C564C2 Q53667526-0EC73F5D-44EE-4A6B-BE93-6726DE0A71BD Q56897633-DB442FE3-464E-40D0-A02C-4C09D321B30E Q57193038-9D2CDB86-DD12-4BD7-B606-C7199030694D

P2860

Releasing the brake on the immune system: ipilimumab in melanoma and other tumors

http://www.wikidata.org/entity/Q34447732

description

2010 nî lūn-bûn

@nan

2010 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Releasing the brake on the immune system: ipilimumab in melanoma and other tumors

@ast

Releasing the brake on the immune system: ipilimumab in melanoma and other tumors

@en

Releasing the brake on the immune system: ipilimumab in melanoma and other tumors

@nl

type

label

Releasing the brake on the immune system: ipilimumab in melanoma and other tumors

@ast

Releasing the brake on the immune system: ipilimumab in melanoma and other tumors

@en

Releasing the brake on the immune system: ipilimumab in melanoma and other tumors

@nl

prefLabel

Releasing the brake on the immune system: ipilimumab in melanoma and other tumors

@ast

Releasing the brake on the immune system: ipilimumab in melanoma and other tumors

@en

Releasing the brake on the immune system: ipilimumab in melanoma and other tumors

@nl

P1433

Q34447732-FE24FBD9-6C66-4984-B29A-B58964EE9C08

P1476

Q34447732-11AC603A-8776-4768-B59F-D720667E93AD

P2093

Q34447732-8ED5490B-4ED0-4FA7-81DA-ADF4DC2BF632

Q34447732-AFFFD9F2-6878-4F41-BCB7-8C4D4C3CC962

Q34447732-E956DABB-69E8-47E5-8548-3C971685F76C

P2860

Q34447732-01C109C6-3CFF-4CD8-B2D7-144FE5A94522

Q34447732-12A31357-1897-4DB2-AF02-13283AFB693C

Q34447732-173D760E-D3B6-47D2-BA6E-68EC09ECB0A6

Q34447732-1F110B0D-C003-4B49-A15C-97FFB7A1CCB7

Q34447732-202B77A8-A487-421B-B562-EEC6750148BF

Q34447732-240A7758-4420-4962-9822-37760B7254E7

Q34447732-256F706C-A798-4B50-BCD7-6DCF91D327C4

Q34447732-2DC7B12B-8239-4692-BA0F-6F492C523437

Q34447732-315F3D72-5A33-458C-ACCA-4072669F9B1E

Q34447732-32DBC901-FACE-4B2C-9AB7-18CB3221D91E

P304

Q34447732-3D7C5640-3F04-4DFB-A273-29C11DEC753B

P31

Q34447732-DDFC3ABA-11CC-44E9-80AA-5E3896E6D92D

P356

Q34447732-39A383ED-0813-4131-96DE-645DA7F389DA

P433

Q34447732-CD2F15AF-B8E6-4DC2-9147-714CE360DE17

P478

Q34447732-7C1FAA27-C498-4C54-9222-3B8129738788

P577

Q34447732-DC473716-9B8E-40D7-8324-538D3D2DF5B8

P5875

Q34447732-D69EDEA3-52BD-4B29-9A3E-FE330D17DE06

P698

Q34447732-AE618058-DA86-4BCE-8377-2608657FAC63

P921

Q34447732-4C96FA8A-8181-42B5-A1B4-9109C988952E

P932

Q34447732-A2DE10FD-66A1-4930-8F2B-A5FF8E672C97

P356

P1433

Cancer Biotherapy and Radiopharmaceuticals

P1476

Releasing the brake on the immune system: ipilimumab in melanoma and other tumors

@en

P2093

Ahmad Tarhini

http://www.w3.org/2001/XMLSchema#string

David R Minor

http://www.w3.org/2001/XMLSchema#string

Ernest Lo

http://www.w3.org/2001/XMLSchema#string

P2860

CD28/B7 costimulation: a review

Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation

Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

What is the role of cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma?

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993

Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group.

Phase I study of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with relapsed and refractory B-cell non-Hodgkin lymphoma.

Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival

P304

601-613

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1089/CBR.2010.0865

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

25

http://www.w3.org/2001/XMLSchema#string

P577

2010-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49727408

http://www.w3.org/2001/XMLSchema#string

P698

21204754

http://www.w3.org/2001/XMLSchema#string

P921

P932

3011989

http://www.w3.org/2001/XMLSchema#string